1644670-37-0 ((Iptacopan)

LNP023;8E05T07Z6W;4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid;Iptacopan;Iptacopan [INN];4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid;GTPL10710;BDBM160475;compound 41 [PMID: 32073845];4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid;4-[(2~{S},4~{S})-;Unii-8E05T07Z6W;IPTACOPAN [WHO-DD];Factor B Inhibitor LNP023;1644670-37-0;FABHALTA;Iptacopan [USAN:INN];iptacopanum;Benzoic acid, 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]-;AT30389;CS-0093107;SCHEMBL16400416;GLXC-20953;MS-27420;4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl) benzoic acid;Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-;NVP-LNP023;4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid;AKOS040733609;NVP-LNP023-NX;EX-A5728;JGQ;LNP 023;LNP-023;4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid;US9682968, Example-26a;WHO 11259;CHEBI:229652;Iptacopan [USAN];HY-127105;LNP023?;DA-75063;RENRQMCACQEWFC-UGKGYDQZSA-N;CHEMBL4594448;

RENRQMCACQEWFC-UGKGYDQZSA-N

1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1

O(CC)[C@H]1CCN(CC2=C(C=C(C)C3=C2C=CN3)OC)[C@H](C2C=CC(C(=O)O)=CC=2)C1